Een open label studie met een enkelvoudige dosering om de pharmacokinetiek te onderzoeken van CG5503 immediate release capsule in gezonde oudere en jongere vrijwilligers

Gepubliceerd: 23-08-2006 Laatst bijgewerkt: 20-05-2024

The purpose of the study is to compare the single dose pharmacokinetics of CG5503 between healthy elderly and young adult men and women (pharmacokinetics means that will be studied how the body absorbs, distributes and eliminates the investigated…

Ethische beoordeling	Goedgekeurd WMO
Status	Werving gestopt
Type aandoening	Overige aandoening
Onderzoekstype	Interventie onderzoek

Samenvatting

ID

NL-OMON30712

Bron
ToetsingOnline

Verkorte titel
CG5503 IR Pharmacokinetiek in jongeren en ouderen

Aandoening

- Overige aandoening

Synoniemen aandoening
chronische pijn, pijn

Aandoening

acute en chronische pijn

Betreft onderzoek met
Mensen

Ondersteuning

Primaire sponsor: Johnson & Johnson Pharmaceutical
Overige ondersteuning: Johnson and Johnson Pharmaceutical Research and Development LLC;in the Netherlands represented by Janssen-Cilag B.V.;Dr. Paul Janssenweg 150;5026 RH Tilburg.

Onderzoeksproduct en/of interventie

Trefwoord: CG5503, pharmacokinetiek, pijn

Uitkomstmaten

Primaire uitkomstmaten

Pharmacokinetics: plasma and urine CG5503 and CG5503-O-glucuronide

concentrations, pharmacokinetic parameters

Safety: adverse events, vital signs, ECG-parameters, laboratory parameters,

physical examination

Secundaire uitkomstmaten

nvt

Toelichting onderzoek

Achtergrond van het onderzoek

The drug to be given, CG5503, is a new, investigational compound that may eventually be used for the treatment of acute and chronic pain. CG5503 is a centrally active analgesic and it partly works as the current marketed opium like medicines.

Doel van het onderzoek

The purpose of the study is to compare the single dose pharmacokinetics of CG5503 between healthy elderly and young adult men and women (pharmacokinetics means that will be studied how the body absorbs, distributes and eliminates the

investigated compound). In addition, the safety and tolerability of the compound will be examined in healthy elderly and young adults.

Onderzoeksopzet

Open-label, single-center study comparing the pharmacokinteics of CG5503 base and its metabolite, CG5503-O-glucuronide, in healthy elderly and young adult subjects

Screening and follow-up: clinical laboratory, full physical examination, ECG; at eligibility screening: medical history, drug screen, HBsAg, anti HCV, anti-HIV 1/2 and pregnancy test (females only); vital signs, pregnancy test and drug and alcohol screen repeated upon admission

Observation period: one period in clinic from -17 h up to 48 h after drug administration

Blood sampling: for pharmacokinetics: pre-dose and at 0.5, 1, 1.5, 2, 3, 4, 6, 9, 12, 16, 24, 36 and 48 h post-dose; for genotyping: pre-dose on day 1

Urine sampling: for pharmacokinetics: pre-dose and from 0-6, 6-12, 12-24, 24-48 h post-dose

Safety assessments: adverse events: throughout the study; vital signs: pre-dose and at 24 h post-dose; ECG: pre-dose; clinical laboratory: pre-dose; creatinine sample: at 12 h post-dose; pregnancy test: 48 h post-dose

Bioanalysis: by Sponsor

Onderzoeksproduct en/of interventie

Study medication Active substance: CG5503 base Activity: morphine analogue Indication: pain relieve Strength: 80 mg Dosage form: oral capsule Treatments a single dose of 80 mg CG5503 base

Inschatting van belasting en risico

Procedures: pain, light bleeding, haematoma, possibly an infection.

Medication: The safety of CG5503 has been determined in the 12 completed Phase 1 studies, in which 286 healthy subjects received either 2 minute or 15 minute i.v. infusions of CG5503, single oral doses of the immediate release (IR) capsule or the prolonged release (PR) tablet, or multiple oral doses (twice daily) of the PR tablet, and in the seven completed Phase 2 studies, in which 1504 subjects with acute or chronic pain received single or multiple oral doses of the CG5503 IR capsule or the PR tablet.

Single- and multiple dose administrations of the CG5503 IR capsule and the PR tablet were well tolerated. The side effects profile was consistent with that of a centrally acting analgesic (e.g. morphine). Most side effects were mild, of short duration, and resolved spontaneously. Overall, when the dose of medication was increased, there were more side effects.

Phase 1
In Phase 1 studies in healthy subjects, the most common side effects after single dose administration (25 to 200 mg) of the CG5503 IR capsule were fatigue, dizziness, sleepiness, headache, and dry mouth. At the same doses, CG5503 has fewer side effects like nausea and vomiting, when compared to other painkillers like tramadol and morphine. The most common adverse events after single dose administration (100 and 200 mg) of the CG5503 PR tablet were headache, fatigue, dizziness, and dry mouth, while the most common side effects after multiple dose administration (100 and 200 mg twice daily) of the PR tablet were fatigue, dizziness, headache and dry mouth. None of the treatments had a considerable effect on vital signs, electrocardiograms (ECGs), or laboratory parameters.
In one Phase 1 study, a 47-year-old man had an epileptic attack after receiving multiple doses of 200 mg CG5503 PR tablets. He was hospitalized immediately after the event and recovered without further consequences. The subject had a history of seizure, which was not known at the time of commitment to the study, and this volunteer was probably taking anti-epileptic drugs during the trial.

Phase 2 (patient studies)
In Phase 2a studies of single dose administration (25 to 200 mg) of the IR capsule to subjects with postoperative pain, the most common side effects were nausea, dizziness, vomiting, sleepiness and headache. At higher doses, several subjects had light signs of respiratory depression, which were not considered serious and were solved by speaking directly to the patient. In Phase 2a studies of multiple dose (25 and 50 mg given 4 times daily) administration of the IR capsule to subjects with postoperative or chronic pain, the most common side effects were headache, nausea, dizziness, vomiting, sleepiness, and constipation.
In Phase 2b studies of multiple dose administration (25, 50, and 100 mg twice daily) of the CG5503 PR tablet to subjects with either chronic osteoarthritis (OA) or chronic low back pain (LBP), the most common side effects were nausea, headache, dizziness, vomiting, and sleepiness.

ICF amendement d.d. 22Dec06, additional to section above:
Dear volunteer,

The study for which you have shown interest has temporarily been paused recently and PRA wants to inform you about the reason. For this, the following amendment to the Informed Consent Form is made.

The conduct of the study was temporarily paused because an adverse event, which

had occurred in one subject after administration of the study medication, had to be evaluated thoroughly. This adverse event comprised a short-lasting sudden loss of consciousness interpreted as respiratory arrest by the investigator.
The subject recovered without any negative effects.
After thorough and intensive investigations, the assessment was made that this case does not change the risk and safety profile of the study medication which has been explained to you in the Informed Consent Form. Thus, the current study will be continued under the same conditions as originally planned. Limited to this particular study, telemetric ECG monitoring and pulse oximetry during 4 hours after drug administration will be performed. These non-invasive measures mean that ECG electrodes will be applied on your skin for telemetric ECG monitoring and a finger-clip device will be attached on one finger for pulse oximetry. These measures would provide the medical investigator continuous information about heart and lung function to optimize adequate diagnostics.

In case of questions we ask you to direct them to the medical investigator of this study.

Contactpersonen

Publiek

Johnson & Johnson Pharmaceutical

Dr. Paul Janssenweg 150
5026 RH Tilburg
Nederland

Wetenschappelijk

Johnson & Johnson Pharmaceutical

Dr. Paul Janssenweg 150
5026 RH Tilburg
Nederland

Locaties

Landen waar het onderzoek wordt uitgevoerd

Netherlands

Deelname eisen

Leeftijd
Volwassenen (18-64 jaar)
65 jaar en ouder

Belangrijkste voorwaarden om deel te mogen nemen (Inclusiecriteria)

man
vrouw (minimaal 2 jaar postmenopauzaal, chirurgisch gesteriliseerd of gebruik makend van voor dit onderzoek adequate anticonceptie methode)
leeftijd tussen 18 en 45 jaar
leeftijd 65 jaar of ouder
BMI tussen 20 * 30 kg/m2 met een gewicht van minimaal 50 kg
niet roker of lichte roker
Nier functie: voor ouderen een CLCR hoger dan 60 mL/min; voor jongeren een CLCR van minimaal 80 mL/min

Belangrijkste redenen om niet deel te kunnen nemen (Exclusiecriteria)

Lijdend aan: ernstige aandoening zoals bijvoorbeeld hepatitis B, kanker of HIV/AIDS.
Indien gedurende de 60 dagen voorafgaand aan de start van dit onderzoek aan een ander geneesmiddelenonderzoek is deelgenomen.
Indien gedurende de 90 dagen voor start van dit onderzoek bloed gegeven of plotseling bloedverlies gehad van een gelijkwaardige hoeveelheid bloed.

Onderzoeksopzet

Opzet

Type: Interventie onderzoek

Blindering:	Open / niet geblindeerd
Controle:	Geen controle groep
Doel:	Behandeling / therapie

Deelname

Nederland	
Status:	Werving gestopt
(Verwachte) startdatum:	20-09-2006
Aantal proefpersonen:	32
Type:	Werkelijke startdatum

Ethische beoordeling

Goedgekeurd WMO Datum:	23-08-2006
Soort:	Eerste indiening
Toetsingscommissie:	BEBO: Stichting Beoordeling Ethiek Bio-Medisch Onderzoek (Assen)
Goedgekeurd WMO Datum:	04-09-2006
Soort:	Eerste indiening
Toetsingscommissie:	BEBO: Stichting Beoordeling Ethiek Bio-Medisch Onderzoek (Assen)
Goedgekeurd WMO Datum:	05-01-2007
Soort:	Amendement
Toetsingscommissie:	BEBO: Stichting Beoordeling Ethiek Bio-Medisch Onderzoek (Assen)
Goedgekeurd WMO Datum:	17-01-2007
Soort:	Amendement
Toetsingscommissie:	BEBO: Stichting Beoordeling Ethiek Bio-Medisch Onderzoek (Assen)

Registraties

Opgevolgd door onderstaande (mogelijk meer actuele) registratie

Geen registraties gevonden.

Andere (mogelijk minder actuele) registraties in dit register

Geen registraties gevonden.

In overige registers

Register	ID
EudraCT	EUCTR2006-003982-15-NL
CCMO	NL13752.056.06